stoxline Quote Chart Rank Option Currency Glossary
  
DURECT Corporation (DRRX)
1.34  0.07 (5.51%)    03-27 16:00
Open: 1.27
High: 1.34
Volume: 188,734
  
Pre. Close: 1.27
Low: 1.2501
Market Cap: 40(M)
Technical analysis
2024-03-27 4:52:25 PM
Short term     
Mid term     
Targets 6-month :  1.68 1-year :  1.96
Resists First :  1.44 Second :  1.68
Pivot price 1.2
Supports First :  1.09 Second :  0.87
MAs MA(5) :  1.26 MA(20) :  1.15
MA(100) :  0.86 MA(250) :  2.72
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  70.7 D(3) :  62.9
RSI RSI(14): 62.9
52-week High :  7.46 Low :  0.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DRRX ] has closed below upper band by 22.4%. Bollinger Bands are 32% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.34 - 1.35 1.35 - 1.36
Low: 1.23 - 1.24 1.24 - 1.25
Close: 1.33 - 1.34 1.34 - 1.35
Company Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Headline News

Wed, 27 Mar 2024
DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023 - InvestorPlace

Wed, 27 Mar 2024
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript - Seeking Alpha

Wed, 27 Mar 2024
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Wed, 27 Mar 2024
DURECT Corp reports results for the quarter ended in December - Earnings Summary - TradingView

Wed, 27 Mar 2024
Durect: Q4 Earnings Snapshot - The Washington Post - The Washington Post

Wed, 27 Mar 2024
Durect: Q4 Earnings Snapshot | News | bakersfield.com - The Bakersfield Californian

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 30 (M)
Shares Float 28 (M)
Held by Insiders 6.3 (%)
Held by Institutions 23.4 (%)
Shares Short 1,060 (K)
Shares Short P.Month 1,160 (K)
Stock Financials
EPS -1.53
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.5
Profit Margin 0 %
Operating Margin -548 %
Return on Assets (ttm) -42.8 %
Return on Equity (ttm) -148.9 %
Qtrly Rev. Growth -85.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.3
EBITDA (p.s.) -1.41
Qtrly Earnings Growth 0 %
Operating Cash Flow -35 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -0.88
PEG Ratio -0.1
Price to Book value 2.68
Price to Sales 4.34
Price to Cash Flow -1.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android